Description

J&J’s Potential $20 Billion DePuy Exit: Why Its $21 Billion Bet Could End!

Johnson & Johnson could be preparing to unwind one of the biggest healthcare bets in its history. Apollo Global Management is reportedly in talks over a possible acquisition of all or part of J&J’s DePuy Synthes orthopaedics business at a valuation close to $20 billion, roughly 14 years after J&J paid $21 billion for Synthes and combined it with DePuy to build a global orthopedics powerhouse. On the surface, the numbers make the transaction look like an expensive round trip. The reality is more complicated. DePuy Synthes generated approximately $9.3 billion in sales last year, and its underlying business is actually improving rather than collapsing. Yet J&J is simultaneously reshaping itself around faster-growing pharmaceuticals, cardiovascular technologies, surgical robotics and other innovation-heavy businesses. Management continues to target a mid-2027 separation of DePuy Synthes while evaluating different structures.